Efficacy and safety of Dorzagliatin in real-world populations with type 2 diabetes: a China multicenter retrospective study (EASTERN Study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600117249

Enrollment

Unknown

Registered

2026-01-21

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Dorzagliatin group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged 18 and above who meet the diagnostic criteria for type 2 diabetes; 2.Continuous use of Dorzagliatin Tablets for more than 6 months; 3.With glycated hemoglobin levels before and after 6 month use the Dorzagliatin.

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with type 1 diabetes and other types of diabetes; 2.Patients who have been continuously using Dorzagliatin for less than 6 months.

Design outcomes

Primary

Measure	Time frame
Hypoglycemia incidence rate;Proportion of patients with glycated hemoglobin<7%;	—

Secondary

Measure	Time frame
Changes in weight;Changes in uric acid;Changes in fasting blood glucose;Changes in total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides;Changes in HbA1c;	—

Countries

China

Contacts

Public ContactWang Yufan

Shanghai General Hospital

yyffwang@sina.com+86 21 6324 0090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026